On August 7, Novo-Nordisk A/S rose 3.15% in regular trading, trading at $46.84/share, with turnover of $81.62 million.

On the news front, the continued rally was driven by a combination of stronger-than-expected Q2 results and a favorable patent ruling in the Netherlands. The company reported adjusted EPS of $0.96, beating the consensus estimate of $0.81 by 18.5%, while sales of $12.209 billion also surpassed the $11.35 billion estimate. The company simultaneously raised its full-year sales and operating profit guidance, primarily driven by elevated GLP-1 product sales expectations.

Additionally, the District Court of The Hague ruled that Ceban Ziekenhuisfarmacie B.V. infringed Novo-Nordisk A/S's supplementary protection certificate covering semaglutide with its compounded nasal spray, issuing a preliminary injunction requiring immediate cessation of sales. This ruling further reinforces the company's intellectual property moat around its core GLP-1 franchise. The stock has now rebounded from a nearly 10% decline triggered by the failure of its ziltivekimab cardiovascular trial, reflecting a market re-rating of the resilience of its core obesity and diabetes business.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)